Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection. - 2Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- 3Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- 4Denny's is shutting down restaurants around the country. What's behind the closures?
- 5Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
- Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- The Development of Shipping: Controlling Towards a More Associated Future
- ‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas
- 4 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- Bonk.fun’s April Fools Joke Targets Israel, Sparks Debate
- A Past filled with Old Civilizations: The World's Most established Societies
- High-Suggested Broilers For Your Homes
- 5 Home EV Chargers for Proficient and Solid Charging
- Data centers in space: Will 2027 really be the year AI goes to orbit?
